Literature DB >> 12970115

Arterial endothelium-specific activin receptor-like kinase 1 expression suggests its role in arterialization and vascular remodeling.

Tsugio Seki1, Jihye Yun, S Paul Oh.   

Abstract

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular disorder characterized by epistaxis, mucocutaneous telangiectases, and arteriovenous malformations (AVM). Two genes are linked to HHT: endoglin (ENG) in HHT1 and activin receptor-like kinase 1 (ACVRL1; ALK1) in HHT2. Although both genes are involved in the transforming growth factor beta signaling pathways, the pathogenetic mechanisms for HHT remain elusive. It was shown that mutations in the Alk1 gene in mice and zebrafish resulted in an embryonic lethal phenotype due to severe dilation of blood vessels. We created a novel null mutant mouse line for Alk1 (Alk1lacZ) by replacing its exons, including the one that encodes the transmembrane domain, with the beta-galactosidase gene. Using Alk1lacZ mice, we show that Alk1 is predominantly expressed in developing arterial endothelium. Alk1 expression is greatly diminished in adult arteries, but is induced in preexisting feeding arteries and newly forming arterial vessels during wound healing and tumor angiogenesis. We also show that hemodynamic changes, which require vascular remodeling, may regulate Alk1 expression. Our studies suggest the role of Alk1 signaling in arterialization and remodeling of arteries. Contrary to the current view of HHT as venous disease, our findings suggest that the arterioles rather than the venules are the primary vessels affected by the loss of an Alk1 allele, and that blood vessels with reduction in Alk1 expression may harbor defects in responding to demands for vascular remodeling.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970115     DOI: 10.1161/01.RES.0000095246.40391.3B

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  102 in total

1.  Differential role of Nkx2-5 in activation of the atrial natriuretic factor gene in the developing versus failing heart.

Authors:  Sonisha A Warren; Ryota Terada; Laura E Briggs; Colleen T Cole-Jeffrey; Wei-Ming Chien; Tsugio Seki; Ellen O Weinberg; Thomas P Yang; Michael T Chin; Jörg Bungert; Hideko Kasahara
Journal:  Mol Cell Biol       Date:  2011-09-19       Impact factor: 4.272

Review 2.  Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Ther Deliv       Date:  2011-08

Review 3.  Bone Morphogenetic Protein functions as a context-dependent angiogenic cue in vertebrates.

Authors:  David M Wiley; Suk-Won Jin
Journal:  Semin Cell Dev Biol       Date:  2011-10-12       Impact factor: 7.727

Review 4.  Endothelial cell heterogeneity and atherosclerosis.

Authors:  William C Aird
Journal:  Curr Atheroscler Rep       Date:  2006-01       Impact factor: 5.113

5.  Essential role of endothelial Smad4 in vascular remodeling and integrity.

Authors:  Yu Lan; Bing Liu; Huiyu Yao; Fangfei Li; Tujun Weng; Guan Yang; Wenlong Li; Xuan Cheng; Ning Mao; Xiao Yang
Journal:  Mol Cell Biol       Date:  2007-08-27       Impact factor: 4.272

Review 6.  Blood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

7.  ALK1 signaling regulates early postnatal lymphatic vessel development.

Authors:  Kyle Niessen; Gu Zhang; John Brady Ridgway; Hao Chen; Minhong Yan
Journal:  Blood       Date:  2009-11-10       Impact factor: 22.113

Review 8.  Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma.

Authors:  Paulina Kozakiewicz; Ludmiła Grzybowska-Szatkowska
Journal:  Oncol Lett       Date:  2018-03-20       Impact factor: 2.967

Review 9.  Biology of vascular malformations of the brain.

Authors:  Gabrielle G Leblanc; Eugene Golanov; Issam A Awad; William L Young
Journal:  Stroke       Date:  2009-10-15       Impact factor: 7.914

10.  A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors.

Authors:  Laura W Goff; Roger B Cohen; Jordan D Berlin; Filippo G de Braud; Andrej Lyshchik; Cristina Noberasco; Francesco Bertolini; Marina Carpentieri; Corrado Gallo Stampino; Antonello Abbattista; Erjan Wang; Hossein Borghaei
Journal:  Clin Cancer Res       Date:  2015-12-11       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.